共 2 条
[1]
[2]
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1<ce:hsp sp="0.25"/>M tegafur–0.4<ce:hsp sp="0.25"/>M gimestat–1<ce:hsp sp="0.25"/>M otastat potassium) in advanced gastric cancer patients.[J].Y Sakata;A Ohtsu;N Horikoshi;K Sugimachi;Y Mitachi;T Taguchi.European Journal of Cancer.1998, 11

